***Background.*** No IV antiviral agents for the treatment of severe influenza are currently approved in the U.S. Since 2009, IV zanamivir has been authorized for compassionate use through an Emergency Investigational New Drug (EIND) application to the Food and Drug Administration (FDA) as an investigational treatment for patients with serious influenza infection. We report the compassionate use of IV zanamivir in 3 patients at Cedars-Sinai Medical Center during the 2013-2014 influenza season.

***Methods.*** Use of IV zanamivir was approved by the institution\'s investigational review board and an EIND was granted by the FDA for each patient. We performed a descriptive analysis of demographics, vaccination status, baseline co-morbidities, virologic test results, other antiviral treatments, supportive care modalities, treatment duration, adverse events and 30 day-outcome.

***Results.*** The decision to start IV zanamivir and the duration of therapy depended on the clinical judgment of the treating physician. IV zanamivir was initiated after a lack of clinical improvement from oseltamivir use. At the time of EIND request, all three patients were in the intensive care unit with respiratory failure and acute respiratory distress syndrome. All patients received a 5 day course of IV zanamivir. No medication related adverse events were identified. Please see the table for further details.

                                                                        Patient 1               Patient 2                Patient 3
  --------------------------------------------------------------------- ----------------------- ------------------------ ----------------------------------
  Age (years)                                                           63                      34                       29
  Gender                                                                Female                  Female                   Male
  Vaccination status                                                    Unknown                 Not vaccinated           Unknown
  Co-morbidities                                                        Hypertension, smoking   None                     Morbidly obese
  Influenza strain                                                      A, not typed            2009 H1N1                A, not typed
  Duration (days) of influenza symptoms prior to starting oseltamivir   5                       7                        2
  Duration (days) of oseltamivir prior to starting zanamivir            9                       5                        13
  Supportive care                                                       ECMO                    Mechanical ventilation   ECMO
  Superimposed bacterial pneumonia                                      MSSA                    None                     MSSA, *Streptococcus pneumoniae*
  30-day Outcome                                                        Death                   Survived                 Survived

Key: MSSA (Methicillin susceptible *Staphylococcus aureus*), ECMO (extracorporeal membrane oxygenation)

***Conclusion.*** In addition to efficacy and activity against oseltamivir resistant strains, IV zanamivir offers an important alternative route of administration in critically ill patients with severe influenza.
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